by Kevin Dooley, MD | Mar 30, 2021 | News and Information
Negative Results The biotech company Orphazyme announced negative results yesterday for the clinical trial of arimoclomol in the treatment of inclusion body myositis (IBM). The drug failed to meet the primary and secondary endpoints which were used to measure success.... 
by Kevin Dooley, MD | Mar 19, 2020 | News and Information
AAVogen, an early-stage biotech company, is developing a new treatment for inclusion body myositis (IBM). AVGN7 is a novel gene therapy treatment that is designed to treat IBM and other muscle wasting conditions. AAVogen has raised $2.3 million to date, mostly from... 
by Kevin Dooley, MD | Apr 22, 2019 | News and Information
Researchers at the Yale School of Medicine in New Haven, CT are looking for patients with inclusion body myositis (IBM) to participate in a study using Electrical Impedance Myography (EIM). The purpose of the study is to learn if EIM is useful for measuring the... 
by Kevin Dooley, MD | Jan 7, 2019 | News and Information
Washington University School of Medicine in St. Louis, MO, has announced the opening of an IBM Specialty Clinic devoted to inclusion body myositis. The clinic is run by Dr. Conrad “Chris” Weihl, a leading IBM clinician and researcher. Washington University is known... 
by Kevin Dooley, MD | Nov 5, 2018 | News and Information
How do you know if a muscle disease like inclusion body myositis (IBM) is getting worse? How do you compare one patient to another? How do you decide if a new drug is working to slow the gradually worsening muscle weakness that is typical of this disease? How do you... 